Women's Health Market Strategies - Opportunities remain in this overlooked therapy area | ReportsnReports
Upcoming SlideShare
Loading in...5
×
 

Women's Health Market Strategies - Opportunities remain in this overlooked therapy area | ReportsnReports

on

  • 614 views

 

Statistics

Views

Total Views
614
Views on SlideShare
614
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Women's Health Market Strategies - Opportunities remain in this overlooked therapy area | ReportsnReports Women's Health Market Strategies - Opportunities remain in this overlooked therapy area | ReportsnReports Document Transcript

  • Women’s Health Market Strategies – Opportunities remain in this overlooked therapy areaInvestment in women’s health has suffered in recent years as the pharmaceutical industry movestowards specialist care and biological therapies. The traditional view is that women’s health bearsseveral barriers to entry that limit return and deter investment, such as high market competition,stigma, and regulatory restrictions. Nevertheless, opportunities remain in this overlooked therapyarea. Features and benefitsAnalyze the leading players involved in women’s health, including SWOT analyses and franchiserevenue projections to 2016.Clinical and commercial attractiveness assessment of key women’s health indications to identify thebest markets to enter.Identify key marketing and corporate strategies used by current women’s health companies andunderstand the impact of key recent licensing deals.PESTL analysis provides further exploration of the major drivers and resistors in the women’s healthsector.Analysis of sales trends and FDA approvals in women’s health compared to other therapy areas. More Information on: Women’s Health Market StrategiesHighlightsIn 2010, the women’s health market generated $12bn sales for the top 50 drug companies,accounting for 2.1% of total pharmaceutical sales. Bayer-Schering is the leading player in the sectorwith sales nearing $3bn in 2010 and will continue to dominate the market. Other key players includePfizer, Warner Chilcott, Teva, Merck KGaA, and Merck & Co.The decreasing interest in women’s health is due to the perceived poor return on investmentcompared to other sectors. There are several barriers to entry, including high stigma, poor treatmenteducation, regulatory restrictions, and lack of scientific innovation. The perceived lower level ofunmet need and high competition further deter investment Browse All : Market Research ReportsCompanies can increase the patient potential of their products by raising awareness, destigmatizingconditions, and dispelling safety concerns utilizing modern day marketing channels. Moreover,portfolios can be further optimized by expansions into non-traditional women’s health disorders andnew geographies, particularly India and China.
  • Table Of ContentsOVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusReport structureDatamonitor key findingsRelated reportsWOMEN’S HEALTH MARKET DYNAMICSKey findingsMarket definitionTrends in pharmaceutical salesSmall molecules will continue to display strong growth in the women’s health area, unlike the rest ofthe industryOver the forecast period there will be less generic erosion in women’s health compared to rest of thesectorMergers and acquisitions are the key source of products for companies involved in the women’shealth sectorTrends in FDA approvalsFDA approvals remain below the industry averageKey market eventsHormone replacement therapy for menopausal symptoms – BZA/CE meets Phase III endpoints andcontinues its bid to reinvigorate the HRT marketHormonal contraception – potential new bestseller Zoely is approved in the EUNon-hormonal therapy for menopausal symptoms – Pristiq is unlikely to target gap in the menopausemarket as the FDA fails to approve the therapyFemale sexual dysfunction – Boehringer Ingelheim withdraws flibanserin, further reducing thepotential of this marketEndometriosis – Abbott safeguards market leadership through elagolix dealMARKETING AND CORPORATE STRATEGIES IN WOMEN’S HEALTHKey findingsTrends in deals and alliancesConsolidation among the Big Pharma peer set threatens the sector…but opportunities exist for companies wanting to take the riskThere were 74 deals and alliances in women’s health from 2010 to 2011Trends in marketing strategiesDirect-to-consumer advertisingSponsorship/disease awareness campaignsTrends in corporate strategiesCompanies target women’s health disorders as secondary indicationsCompanies focus on one or two marketsBranded generics are common in the hormonal contraceptive marketsKEY WOMEN’S HEALTH PLAYERSKey findings
  • Strategic overviewBayer-Schering – the hormonal contraceptive companyBayer-Schering’s women’s health portfolio accounts for over 22% of the company’s total salesIndication expansions and a broad portfolio are key to Bayer-Schering’s success in the sectorBayer-Schering focuses on endometriosis while turning away from hormone replacement therapiesSWOT analysis for Bayer-Schering’s women’s health portfolioPfizer – the HRT companyWomen’s health sales only account for 2.6% of total salesPfizer can restore growth in the menopausal marketSWOT analysis for Pfizer’s women’s health portfolioTeva – the opportunistic companySWOT analysis for Teva’s women’s health portfolioWarner Chilcott – the specialist companyWomen’s health sales only account for 22.5% of total salesWarner Chilcott expands its franchise to included non-traditional women’s health productsSWOT analysis for Warner Chilcott’s women’s health portfolioMerck KGaA – the infertility companyMerck KGaA continues to invest in the infertility market but has divested its hormonal contraceptivesfranchiseSWOT analysis for Merck KGaA’s women’s health portfolioMerck & Co. – the ambiguous companySWOT analysis for Merck & Co.’s women’s health portfolioWOMEN’S HEALTH MARKET ACCESSKey findingsOpportunities and threatsDatamonitor’s market attractiveness assessmentKey takeoutsUnmet needsPESTL analysisPoliticalEconomicalSocialTechnologicalLegalREDEFINING WOMEN’S HEALTHKey findingsOpportunities exist beyond “traditional” gynecological women’s health disordersMany disorders affect women disproportionately and could be considered women’s health disordersPostmenopausal care presents the greatest patient populationCompanies entering very competitive markets can decide to target women, providing differentiationCompanies involved in diseases that are more prevalent in women are targeting this population intheir websitesIncluding women in clinical trials to assess gender differences in drug efficacy and safetyBIBLIOGRAPHYJournal papers
  • WebsitesDatamonitor reportsAPPENDIXContributing expertsPharmaVitae Explorer databaseConferences attendedReport methodologyLIST OF TABLESTable: Global sales and growth of the top 50 pharmaceutical companies, by therapy area ($bn),2006–16Table: Global sales for key pipeline products in the women’s health market, 2011–16Table: Key events in the women’s health market, June 2010–September 2011Table: Top 10 mergers and acquisitions, by value, 2007–11Table: Examples of drug advertising campaigns in women’s health, 2009–11Table: Behavioral intention after seeing an advertTable: Examples of key women’s health awareness campaigns, 2011Table: Key companies involved in women’s health, by indication, 2011Table: Key companies active in the osteoporosis market, 2011Table: Bayer-Schering’s women’s health global sales, 2006–16Table: Bayer-Schering’s – SWOT analysis for women’s health franchise, 2011Table: Pfizer women’s health global sales, 2006–16Table: Pfizer – SWOT analysis for women’s health franchise, 2011Table: Teva global women’s health sales, 2006–16Table: Teva – SWOT analysis for women’s health franchise, 2011Table: Warner Chilcott global women’s health sales, 2006–16Table: Warner Chilcott – SWOT analysis for women’s health franchise, 2011Table: Merck KGaA global women’s health sales, 2006–16Table: Merck KGaA – SWOT analysis for women’s health franchise, 2011Table: Merck & Co. global women’s health sales, 2006–16Table: Merck & Co. – SWOT analysis for women’s health franchise, 2011Table: Women’s health sector opportunities and threatsTable: Prevalence for key indicationsTable: Unmet needs in women’s healthTable: Diagnostic experience with endometriosis according to the type of physician seen firstTable: Recommended treatments for key women’s health conditions during reproductive ageTable: Side effects and safety of key drugs and procedures in women’s healthTable: Women’s health sector market drug competition attractiveness assessment, 2011Table: Reimbursement of in vitro fertilization treatmentsTable: Representative formulary tier status in the US for leading women’s health brands, 2011Table: Examples of governmental and philanthropic organizations involved in women’s healthTable: FDA-approved women’s health specific devices, 2000–11Table: Summary of legal lawsuits open with Merck & Co. and Bayer-Schering, 2011Table: Drug classification for pregnant women, 2011Table: Patient population of diseases affecting women in the US according to PhRMA
  • LIST OF FIGURESFigure: Women’s health disorders, by life stageFigure: Global sales of the top 50 pharmaceutical companies, by therapy area ($bn), 2006–16Figure: Global sales growth of the top 50 pharmaceutical companies, by therapy area ($bn), 2006–16Figure: Forecast top 50 prescription pharmaceutical sales growth, by molecule type (%), 2010–16Figure: Forecast prescription pharmaceutical sales growth, by product lifecycle stage (%), 2010–16Figure: Forecast prescription top 50 pharmaceutical sales growth, by source (%), 2010–16Figure: Number of drugs approved by the FDA, 1995–2011Figure: Deals and alliances in key pharmaceutical areas, 2005–11Figure: Deals and alliances women’s health, 2010–11Figure: Deals and alliances women’s health, by type of deal, 2010–11Figure: Direct-to-consumer pharmaceutical advertising expenditure in the US, 1998–2009Figure: Birds and Bees can’t always make babies campaign, 2011Figure: Disease awareness campaigns, 2011Figure: Branded, generic, and branded generic products in the hormonal contraceptive market in theUS, 2009Figure: Bayer-Schering’s global sales, 2002–16Figure: Bayer-Schering’s global women’s health sales, 2002–16Figure: Pfizer global sales, 2002–16Figure: Pfizer global women’s health sales, 2002–16Figure: Teva global sales, 2002–16Figure: Teva’s global women’s health sales, 2002–16Figure: Warner Chilcott global sales, 2002–16Figure: Warner Chilcott’ s global women’s health,2002–16Figure: Merck KGaA global sales, 2002–16Figure: Merck KGaA’s global women’s health, 2002–16Figure: Merck & Co. global sales, 2002–16Figure: Merck & Co.’ global women’s health sales, 2002–2016Figure: Women’s health sector attractiveness assessment, 2011Figure: Women’s health sector clinical attractiveness ratings, 2011Figure: Women’s health sector commercial attractiveness ratings, 2011Figure: Breakdown of age at diagnosis of female infertility in the seven major markets, 2008Figure: Trends in assisted reproduction technology in the US, 1999–2008Figure: Total Food and Drug Administration approved devices, 2000–11Figure: Food and Drug Administration approved devices, by therapy area, 2000–11Figure: US and EU public- and venture-capital-backed private companies, by segment and therapyarea, 2009Figure: Hip and knee replacements in the UK, by gender, 2010Figure: Pipeline for key therapy sectors, 2011Figure: Women’s health clinical pipeline, 2011Figure: Number of women in the seven major markets, 2011 and 2021Figure: Examples of Detrol LA television marketing campaigns, 2010Figure: Detrol LA (tolterodine; Pfizer) webpage, 2010
  • Figure: Vesicare (solifenacin; Astellas) webpage, 2011Figure: Prolia (denosumab; Amgen/GlaxoSmithKline) webpage, 2011Figure: Pristiq (desvenlafaxine; Pfizer) webpage, 2011Figure: Savella (milnacipran; Forest) webpage, 2011Figure: Topamax (topiramate; Johnson & Johnson) webpage, 2011Figure: Treximex (sumatriptan and naproxen; GlaxoSmithKline) webpage, 2011Figure: Gilenya (fingolimod; Novartis) webpage, 2011Figure: Belysta (belimumab; Human Genome Sciences/GlaxoSmithKline) webpage, 2011Figure: The PharmaVitae ExplorerRelated Market Research Reports:The Future of Life: Forecast Highlights 2011Express Benchmarking 2011 – PolandExpress Benchmarking 2011 – SpainProduct Profiles: HIV – Growing number of FDCs further commoditizes the HIV marketUK Remote Shopping 2012 – the Main Pillar of Multichannel RetailingExpress Benchmarking 2011 – HungaryExpress Benchmarking 2011 – NorwayAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depth marketresearch studies & analysis of over 5000 micro markets. We provide 24/7 online and offline supportto our customers. Get in touch with us for your needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit Our Blog : Market Research Reports